Phase 4 N=171 Attention Deficit Disorder Medication Response Study
ADHD - Inattentive Type · ADHD - Combined Type
Primary: Attention Deficit Hyperactivity Disorder Total Symptom Score — 21.4; 30.0; 20.2; 29.7 units on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Development of a Multi-faceted Cognitive Training Program for Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Total ADHD Symptom Score From Vanderbilt ADHD Parent Rating Scale — 25.94; 28.28 units on a scale — p=.35
Phase 4 N=21 Omega-3 Supplementation to ADHD Medication in Children
Attention Deficit Hyperactivity Disorder · Deficient Emotional Self-Regulation
Primary: Emotional Control Subscale of the Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent) — 65.3; 58.4 units on a scale
Phase 3 N=52 Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
Attention Deficit-Hyperactivity
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In — 37.2 score on a scale
Phase 4 N=60 Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) Total Score at Week 4 — 52.6; -10.9 Unit on a scale
Phase 4 N=96 Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Attention Deficit / Hyperactivity Disorder Total Sum Score of All 18 ADHD Symptom Items — 26.54; 25; 18.94; 18.46 Score
N/A N=76 Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)
Brain Injury
Primary: Neuropsychological Assessment, CVLT-II — 51.3; 51.8; 51.9; 57.2 units on a scale — p=<0.04
N/A N=92 Trial on the Effect of Media Multi-tasking on Attention to Food Cues and Cued Overeating
Attention Concentration Difficulty · Obesity, Childhood
Primary: Amount of Time Spent Looking at Food Cues While Playing a Media Game — 9304.26; 10196.45; 8654.48; 8486.79 milliseconds
Phase 3 N=155 Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 8; 126; 0 participants
Phase 4 N=121 Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
Attention Deficit Hyperactivity Disorder · Reading Disorder
Primary: Stop Signal Reaction Time (SSRT) as Derived From the Stop Signal Reaction Time Paradigm — 299.90; 308.82; 265.61; 260.51 milliseconds (msec) — p=0.504
N/A N=130 Attention Bias Modification Training for Young People
Anxiety · Depression
Primary: Threat Bias Measurement at 4-week Post-intervention and 12-week Follow-up — 1.77; 1.72; 1.17; 2.27 milliseconds — p=>.05
Phase 4 N=71 Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials
Attention Deficit Hyperactivity Disorder
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) — 37.0; 15.0 units on a scale
N/A N=117 Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Improvement in ADHD Severity From Baseline to End of Intervention — 3.0; 3.2 units on a scale
Phase 4 N=24 Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Left Ventricle Size — 44.42; 43.57 mm
Phase 2 N=20 Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Total AISRS Score at the End of Double-blind Treatment (Week 8) — -17; -17 units on a scale